Vasoactive intestinal peptide (VIP) as an ovarian protector: prevention against premature ovarian failure during chemotherapy

Y. HERRERO, L. SCOTTI, G. OUBIÑA, N. PASCUALI, R. RAMHORST, D. ABRAMOVICH, AND F. PARBORELL.

Mar del Plata

Congreso; Reunión Anual Conjunta SAIC-SAFE-SAB-SAP; 2019

SAIC-SAFE-SAB-SAP

The ovary, in addition to its endocrine and intraovarian control, is regulated by direct neural inputs of peptidergic nature. Vasoactive intestinal peptide (VIP) was originally isolated from the small intestine and lung tissues as a peptide and plays an important role in ovarian function. Previous studies have shown that VIP immunoreactivity in follicles from different stages. The objective of this study was to determine the effect of VIP on the ovarian function in doxorubicin induced-Premature Ovarian Failure model (POF) developed in mice.To induce POF, doxorubicin (DX, 10mg/kg, i.p.) was applied in F1 mice (C57XBalbC 8 weeks old) on day 1. Control and DX mice underwent sham surgery and received an intrabursal injection of saline solution, while DX + VIP groups received either 1μl or 10 µl (1 µM) under the bursa of both ovaries, 1 h prior to DX administration. Sacrifices were made at day 15. The ovaries were isolated for histological analysis and protein extraction for Western Blot assays. For all data analysis ANOVA followed by Tukey test were performed. An ovarian morphological analysis showed that DX decreased the % of primary (PriF), preantral (PF) and early antral follicles (EAF), and increased the % of atretic follicles (AtrF) (p